Paxlovid, the pill against COVID-19 developed by the pharmaceutical company Pfizer, is highly effective in preventing the most severe effects of the coronavirus, according to the results disclosed by the company.
This conclusion is drawn from a study carried out with adult patients at high risk of suffering from a serious picture of the disease; The numbers indicate that the Pfizer pill reduces hospitalizations or deaths by 89 percent.
Of 389 patients who received Paxlovid, only three ended up hospitalized. In contrast, of 385 patients who received a placebo pill, 27 were hospitalized and seven died.
For Pfizer, these data are important because “they suggest that the oral pill has the potential to save lives, reduce the severity of infections and prevent nine out of 10 hospitalizations.”
But before its application, Paxlovid has to be authorized by the respective organizations. In the United States, Pfizer announced that the tests will not go ahead and that it will release the study data to the Food and Drug Administration (FDA) for approval for emergency use.
If the FDA approves the COVID-19 pill, the treatment will consist of three pills given twice a day.
This pill has been in development since the beginning of 2021 by Pfizer and there have been several phases of testing with generally promising results. However, it is not yet clear when this treatment could begin to be applied in a general way, although Pfizer hopes that the documentation – and potential approval – will be ready before the end of the year.
A pill like Paxlovid has the potential to radically change the treatment against the disease, which until now has only been attacked with vaccines and which, despite scientific evidence, has quite a few detractors.